Rituximab in Combination with Glucocorticoids for Treating Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (TA308)

Technology Appraisal Guidance No. 308

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Rituximab, in combination with glucocorticoids, is recommended as an option for inducing remission in adults with anti-neutrophil cytoplasmic antibody [ANCA]-associated vasculitis (severely active granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis), only if:

  • further treatment with cyclophosphamide would exceed the maximum amount of cylophosphamide they can have or
  • cyclophosphamide treatment is unsuitable or cannot take it or
  • cyclophosphamide may affect their fertility in those wishing to have children or
  • the condition has stayed active or got worse after a course of cyclophosphamide lasting 3-6 months or
  • the cancer has affected the lining of the bladder and other parts of the urinary system.

1.2 People currently receiving treatment initiated within the NHS with rituximab that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA308

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:nice@nice.org.uk

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Issue Date: March 2014

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

First COVID-19 vaccine approved for use in the UK from next week

First COVID-19 vaccine approved for use in the UK from next week

The MHRA has approved the COVID-19 vaccine developed...

SGLT2 inhibitors summarised in new MIMS table

SGLT2 inhibitors summarised in new MIMS table

Prescribers can quickly compare key features and benefits...